MARKET

ENTA

ENTA

Enanta Pharmaceuticals Inc
NASDAQ
5.23
-0.32
-5.77%
Closed 17:16 05/13 EDT
OPEN
5.51
PREV CLOSE
5.55
HIGH
5.60
LOW
5.20
VOLUME
170.99K
TURNOVER
0
52 WEEK HIGH
17.24
52 WEEK LOW
4.090
MARKET CAP
111.57M
P/E (TTM)
-1.0563
1D
5D
1M
3M
1Y
5Y
1D
Evercore ISI Reaffirms Their Buy Rating on Enanta Pharmaceuticals (ENTA)
TipRanks · 2h ago
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Karyopharm Therapeutics (KPTI)
TipRanks · 2h ago
Enanta Pharmaceuticals Reports Q2 2025 Financial Results
TipRanks · 1d ago
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates
NASDAQ · 1d ago
Enanta Pharma Q2 EPS $(1.06) Beats $(1.14) Estimate, Sales $14.93M Miss $15.95M Estimate
Benzinga · 1d ago
Enanta reports Q2 EPS ($1.06), consensus ($1.14)
TipRanks · 1d ago
BRIEF-Enanta Pharmaceuticals Q2 Revenue USD 14.926 Million
Reuters · 1d ago
ENANTA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR ITS FISCAL SECOND QUARTER ENDED MARCH 31, 2025
Reuters · 1d ago
More
About ENTA
More
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
Recently
Symbol
Price
%Change

Webull offers Enanta Pharmaceuticals Inc stock information, including NASDAQ: ENTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENTA stock methods without spending real money on the virtual paper trading platform.